Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095414 | 0.90 | HTT (0.73) | HTTEPHX1EGFRALDH1A1MEN1 | |
| SCHEMBL7097011 | 0.88 | HTT (0.70) | HTTEPHX1ALDH1A1MEN1KMT2A | |
| SCHEMBL7096937 | 0.87 | HTT (0.73) | HTTEGFRALDH1A1MEN1KMT2A | |
| SCHEMBL7100225 | 0.87 | HTT (0.70) | HTTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL14096398 | 0.84 | RAB9A (0.70) | HTTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL7102679 | 0.82 | HTT (0.62) | HTTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL14096252 | 0.79 | HTT (0.61) | HTTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL11553729 | 0.76 | RAB9A (0.63) | HTTEGFRALDH1A1MEN1KMT2A | |
| SCHEMBL2865777 | 0.76 | HTT (0.55) | HTTEPHX1ALDH1A1MEN1KMT2A | |
| SCHEMBL3905888 | 0.75 | MEN1 (0.72) | HTTEGFRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-0878196-B1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6133258-A | PYRIDOTHIAZINE DERIVATIVE; FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS, PAIN, GLAUCOMA | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0878196-A1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | HTT 3396/4885EPHX1 2324/4885EGFR 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.